论文部分内容阅读
目的对比观察联合应用口服曲美他嗪和美托洛尔对心脏X综合征(CSX)患者的临床治疗效果,包括疗效、心肌缺血发作的频率和持续时间以及心脏功能等指标,旨在为临床治疗CSX提供更为可靠的药物。方法将山东省立医院2008年6月～2009年10月收治的49例CSX患者随机分为观察组28例和对照组21例,两组性别和年龄构成比及临床合并症等资料均具有可比性。其中对照组给予常规综合药物治疗,包括钙拮抗剂、硝酸酯类制剂、阿司匹林等。观察组在对照组治疗的基础上,加用曲美他嗪(每次20 mg,1日3次)和美托洛尔(每次6.25～25.00 mg,1日2次),观察两组患者治疗15～20 d后的疗效、24 h心脏缺血事件发生次数和持续时间、心脏功能等指标的变化。结果治疗后,观察组临床治疗总有效率显著高于对照组(分别为78.6%和47.6%,P<0.01),24 h心肌缺血发作次数明显少于对照组[分别为(3.01±0.61)次和(6.07±2.13)次,P<0.01],24 h心肌缺血发作持续时间明显短于对照组(P<0.01),左心室舒张功能显著优于对照组(P<0.01)。结论曲美他嗪联合美托洛尔治疗CSX,临床疗效显著,可改善心脏舒张功能,提高患者生存质量,安全性好,可推荐常规用于CSX的治疗。
Objective To compare the clinical effects of oral trimetazidine and metoprolol on patients with cardiac X syndrome (CSX), including therapeutic efficacy, frequency and duration of myocardial ischemic attack, and cardiac function, CSX provides a more reliable medication. Methods Forty-nine CSX patients admitted to Shandong Provincial Hospital from June 2008 to October 2009 were randomly divided into observation group (n = 28) and control group (n = 21). The two groups were comparable in gender and age composition and clinical comorbidity Sex. The control group was given conventional comprehensive medical treatment, including calcium antagonists, nitrates, aspirin and so on. The observation group was treated with trimetazidine (20 mg once each time, 3 times a day) and metoprolol (6.25 ~ 25.00 mg each time, twice a day) on the basis of the control group. The patients in both groups were treated The curative effect after 15 ~ 20 days, the number and duration of cardiac ischemic events 24 h, changes of heart function and other indicators. Results After treatment, the total effective rate of clinical treatment in observation group was significantly higher than that in control group (78.6% and 47.6%, P <0.01), and the number of myocardial ischemic attack in 24 hours was significantly less than that of control group (3.01 ± 0.61, (6.07 ± 2.13) times, P <0.01]. The duration of 24 h myocardial ischemia was significantly shorter than that of the control group (P <0.01), and the left ventricular diastolic function was significantly better than that of the control group (P <0.01). Conclusion Trimetazidine combined with metoprolol in the treatment of CSX has significant clinical effect, which can improve diastolic function and improve the quality of life of patients. It is safe and can be recommended for the treatment of CSX.